Constellation Pharmaceuticals (NASDAQ:CNST) was downgraded by equities research analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued on Wednesday, BidAskClub reports.
A number of other research analysts also recently issued reports on the company. Robert W. Baird cut their price target on Constellation Pharmaceuticals from $65.00 to $55.00 and set an “outperform” rating on the stock in a report on Wednesday, March 11th. HC Wainwright reaffirmed a “buy” rating and set a $75.00 price objective (up previously from $50.00) on shares of Constellation Pharmaceuticals in a research report on Thursday, May 7th. BMO Capital Markets cut their target price on Constellation Pharmaceuticals from $42.00 to $34.00 and set a “market perform” rating on the stock in a research note on Monday, June 15th. ValuEngine raised shares of Constellation Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, March 3rd. Finally, Zacks Investment Research downgraded shares of Constellation Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, June 3rd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $47.44.
NASDAQ CNST opened at $28.63 on Wednesday. Constellation Pharmaceuticals has a one year low of $6.01 and a one year high of $59.49. The company has a debt-to-equity ratio of 0.12, a quick ratio of 18.75 and a current ratio of 18.75. The company has a market capitalization of $1.20 billion, a price-to-earnings ratio of -9.80 and a beta of 3.62. The company’s 50-day simple moving average is $36.09 and its two-hundred day simple moving average is $36.53.
Constellation Pharmaceuticals (NASDAQ:CNST) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.61) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.62) by $0.01. Equities analysts expect that Constellation Pharmaceuticals will post -2.73 earnings per share for the current fiscal year.
In other news, insider Karen Valentine sold 2,998 shares of the stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $33.57, for a total value of $100,642.86. Following the transaction, the insider now directly owns 2,998 shares of the company’s stock, valued at $100,642.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Emma Reeve sold 760 shares of the firm’s stock in a transaction dated Friday, April 17th. The stock was sold at an average price of $35.29, for a total value of $26,820.40. Following the completion of the transaction, the chief financial officer now owns 760 shares of the company’s stock, valued at $26,820.40. The disclosure for this sale can be found here. Insiders sold a total of 69,856 shares of company stock valued at $3,274,032 over the last ninety days. 10.60% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Meeder Asset Management Inc. purchased a new stake in Constellation Pharmaceuticals in the fourth quarter valued at $36,000. Ameritas Investment Partners Inc. lifted its holdings in shares of Constellation Pharmaceuticals by 26.0% in the 1st quarter. Ameritas Investment Partners Inc. now owns 1,645 shares of the company’s stock valued at $52,000 after buying an additional 339 shares during the period. Royal Bank of Canada boosted its stake in shares of Constellation Pharmaceuticals by 48.4% in the first quarter. Royal Bank of Canada now owns 1,744 shares of the company’s stock worth $55,000 after buying an additional 569 shares during the last quarter. Bank of Montreal Can grew its holdings in Constellation Pharmaceuticals by 43.0% during the fourth quarter. Bank of Montreal Can now owns 1,937 shares of the company’s stock worth $91,000 after acquiring an additional 582 shares during the period. Finally, Victory Capital Management Inc. raised its position in Constellation Pharmaceuticals by 43.4% during the fourth quarter. Victory Capital Management Inc. now owns 2,199 shares of the company’s stock valued at $73,000 after acquiring an additional 666 shares in the last quarter.
About Constellation Pharmaceuticals
Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors.
Read More: How a Back-End Load Mutual Fund Works
Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.